Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Flovent HFA And Ventolin HFA Inhalers Employ Environmentally-Friendly Delivery System New CFC-free propellant delivers the medication patients need while helping to protect the environment MISSISSAUGA, ON -- October 22, 2002 -- GlaxoSmithKline Inc. (GSK) announced the availability of a new environmentally-friendly delivery system for its inhaled asthma formulations Flovent® (fluticasone propionate) and Ventolin® (salbutamol sulphate) in Canada. New FloventÒ HFA and VentolinÒ HFA metered dose inhalers (MDIs) deliver these well-tolerated and effective asthma medications via a chlorofluorocarbon-free (CFC-free) propellant. GSK developed the CFC-free propellant for its MDIs in compliance with the terms of the Montreal Protocol, an international agreement endorsed by more than 170 countries to regulate the use and production of CFCs. For more than forty years, MDIs for diseases such as asthma and COPD (chronic obstructive pulmonary disease) have safely used CFCs as propellants for the medication. While pharmaceutical usage of CFCs as a propellant in MDIs and other inhalation aerosols is minute, the transition to CFC-free MDIs will help to further protect the environment. "While GlaxoSmithKline strives to produce medications that safely and effectively treat medical conditions, we're also committed to protecting the environment," said Dr. Anne Phillips, Vice President, Research & Development and Chief Medical Officer, GlaxoSmithKline. "GlaxoSmithKline has been a leader in the area of respiratory medicine for the past 30 years because of a sustained commitment to improving treatments for diseases such as asthma and COPD. An example of this leadership is our more than $400 million investment to develop effective CFC-free alternatives for Flovent and Ventolin. These new CFC-free inhalers are better for the environment and continue to effectively treat asthma in a way that patients expect." While there is no significant change to the appearance of the inhalers, some patients using the new Flovent HFA or Ventolin HFA inhalers may notice a softer, warmer spray, a slightly different taste and lighter canister. Patients should be assured that these differences are due to the new propellant will not affect the way the medication works. Posters, brochures, tear-off pads and a web page (available at www.gsk.ca) have been developed to help introduce the new products and to support healthcare professionals as they transition patients to Ventolin HFA and Flovent HFA. The transition is expected to be complete by the end of 2002. In addition to receiving approval by the Therapeutics Product Directorate of Health Canada, Ventolin HFA is currently approved in more than 50 countries worldwide and Flovent HFA is approved in more than 25 countries. Flovent HFA is an inhaled corticosteroid and a highly potent anti-inflammatory drug, indicated for the control and maintenance treatment of bronchial asthma in patients 12 months of age and over. Flovent is the first inhaled corticosteroid with a pediatric indication that uses HFA as its propellant. Ventolin HFA is a short-acting beta2-agonist that is indicated for the relief of asthma symptoms in patients four years of age and over. It has a rapid onset and short duration of action which makes it particularly useful for the treatment of symptoms during intermittent attacks, short-term life-saving rescue therapy in severe attacks and prevention of exercise-induced bronchoconstriction. GlaxoSmithKline Inc. - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. In Canada, GlaxoSmithKline employs more than 1,800 people and is a top 25 investor in Canadian research and development, contributing more than $100 million annually. The company is also one of the top 10 corporate charitable donors, investing more than $6.5 million annually and is recognized as one of the 50 best companies to work for in Canada. SOURCE: GlaxoSmithKline Inc E-mail this page to a friend or colleague! To print, use this version